Low-dose pembrolizumab induced complete radiologic and molecular response of posttransplant lymphoproliferative disorder presenting as classical Hodgkin lymphoma

MeSH terms

• Allografts
• Antibodies, Monoclonal, Humanized / administration & dosage
• Antibodies, Monoclonal, Humanized / therapeutic use*
• Antineoplastic Agents, Immunological / administration & dosage
• Antineoplastic Agents, Immunological / therapeutic use*
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• Brentuximab Vedotin / therapeutic use
• Cytarabine / administration & dosage
• Daunorubicin / administration & dosage
• Epstein-Barr Virus Infections / diagnosis
• Epstein-Barr Virus Infections / drug therapy*
• Epstein-Barr Virus Infections / etiology
• Graft vs Host Disease / drug therapy
• Graft vs Host Disease / etiology
• Hematopoietic Stem Cell Transplantation / adverse effects*
• Hodgkin Disease / diagnosis
• Hodgkin Disease / drug therapy*
• Hodgkin Disease / etiology
• Humans
• Immunosuppressive Agents / adverse effects
• Leukemia, Myeloid, Acute / drug therapy
• Leukemia, Myeloid, Acute / etiology
• Leukemia, Myeloid, Acute / therapy
• Male
• Molecular Targeted Therapy*
• Neoplasms, Second Primary / diagnosis
• Neoplasms, Second Primary / drug therapy*
• Neoplasms, Second Primary / etiology
• Postoperative Complications / diagnosis
• Postoperative Complications / drug therapy*
• Postoperative Complications / etiology
• Programmed Cell Death 1 Receptor / antagonists & inhibitors
• Protoporphyria, Erythropoietic / therapy
• Recurrence
• Remission Induction
• Virus Activation
• Young Adult